SEC Tracker
Get the app

Mind Medicine (MindMed) DFTX

Mind Medicine (MindMed) Q2 FY24: net loss $5.9M; diluted EPS −$0.26

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.3
Material contract

Key figures from this report

These are the numbers Mind Medicine (MindMed) reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$5.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.26No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$243.1MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$20.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Mind Medicine (MindMed) files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Myriad Genetics MYGN public float $494M, Jun 30, 2025
  2. Kura Oncology KURA public float $496M, Jun 30, 2025
  3. KalVista Pharmaceuticals KALV public float $499M, Jun 30, 2025
  4. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  5. Arvinas ARVN public float $469M, Jun 30, 2025